MarketCap
Facebook
X
TelegramAuris Medical Holding Ltd. Operating Expenses 2011-2026 | EARS
Annual Operating Expenses Auris Medical Holding Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 7.26 M | 11 M | 24.4 M | 30.2 M | 30.9 M | 21.4 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.9 M | 7.26 M | 20.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
101 M | $ 16.49 | -0.3 % | $ 3.93 B | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.59 | -1.1 % | $ 1.07 B |  Canada |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.5 | 3.22 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.81 | -1.57 % | $ 4.42 M | China |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 75.14 | -1.82 % | $ 1.45 B | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.57 | -3.68 % | $ 401 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 163.09 | -0.61 % | $ 8.11 B | USA |
 |
Champions Oncology
CSBR
|
12.5 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 65.5 | -1.57 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 60.3 | -0.22 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.34 | -0.48 % | $ 1.36 B | Britain |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 3.37 | -1.75 % | $ 3.94 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
46 M | $ 3.04 | -5.0 % | $ 1.09 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
32.9 M | $ 0.59 | - | $ 549 K | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 25.56 | 0.22 % | $ 684 M | USA |